SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Carriaga MT, Henson DE. Liver, gallbladder, extrahepatic bile ducts, and pancreas. Cancer. 1995; 75: 171190.
  • 2
    Tominaga S, Kuroishi T. Biliary tract cancer. Cancer Surv. 1994; 19-20: 125137.
  • 3
    Strom BL, Hibberd PL, Soper KA, et al. International variations in epidemiology of cancers of the extrahepatic biliary tract. Cancer Res. 1985; 45: 51655168.
  • 4
    Henson DE, Albores-Saavedra J, Corle D. Carcinoma of the gallbladder. Histologic types, stage of disease, grade, and survival rates. Cancer. 1992; 70: 14931497.
  • 5
    Henson DE, Albores-Saavedra J, Corle D. Carcinoma of the extrahepatic bile ducts. Histologic types, stage of disease, grade, and survival rates. Cancer. 1992; 70: 14981501.
  • 6
    Kopelson G, Gunderson LL. Primary and adjuvant radiation therapy in gallbladder and extrahepatic biliary tract carcinoma. J Clin Gastroenterol. 1983; 5: 4350.
  • 7
    Takada T, Kato H, Matsushiro T, et al. Comparison of 5-fluorouracil, doxorubicin and mitomycin C with 5-fluorouracil alone in the treatment of pancreatic-biliary carcinomas. Oncology. 1994; 51: 396400.
  • 8
    Falkson G, MacIntyre JM, Moertel CG. Eastern Cooperative Oncology Group experience with chemotherapy for inoperable gallbladder and bile duct cancer. Cancer. 1984; 54: 965969.
  • 9
    Sanz-Altamira PM, Ferrante K, Jenkins RL, et al. A phase II trial of 5-fluorouracil, leucovorin, and carboplatin in patients with unresectable biliary tree carcinoma. Cancer. 1998; 82: 23212325.
  • 10
    Ducreux M, Rougier P, Fandi A, et al. Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin. Ann Oncol. 1998; 9: 653656.
  • 11
    Chen JS, Jan YY, Lin YC, et al. Weekly 24 h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract carcinomas. Anticancer Drugs. 1998; 9: 393397.
  • 12
    Gebbia V, Majello E, Testa A, et al. Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.). Cancer. 1996; 78: 13001307.
  • 13
    Gallardo J, Fodor M, Gamargo C, et al. Efficacy of gemcitabine in the treatment of patients with gallbladder carcinoma: a case report. Cancer. 1998; 83: 24192421.
  • 14
    Castro MP. Efficacy of gemcitabine in the treatment of patients with gallbladder carcinoma: a case report. Cancer. 1998; 82: 639641.
  • 15
    Gallardo JO, Rubio B, Fodor M, et al. A phase II study of gemcitabine in gallbladder carcinoma. Ann Oncol. 2001; 12: 14031436.
  • 16
    Raderer M, Hejna MH, Valencak JB, et al. Two consecutive phase II studies of 5-fluorouracil/leucovorin/mitomycin C and of gemcitabine in patients with advanced biliary cancer. Oncology. 1999; 56: 177180.
  • 17
    Penz M, Kornek GV, Raderer M, et al. Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. Ann Oncol. 2001; 12: 183186.
  • 18
    Mezger J, Sauerbruch T, Ko Y, et al. Phase II study with gemcitabine in gallbladder and biliary tract carcinomas. Onkologie. 1998; 21: 232234.
  • 19
    Bruckner HW, Zhou G, Haenel P, et al. Ex vivo ATP tumor testing of gemcitabine for combination chemotherapy and biochemical modulation [abstract]. Proc Am Assoc Cancer Res. 1998; 39: 310.
  • 20
    Poplin E, Roberts J, Tombs M, et al. Leucovorin, 5-fluorouracil, and gemcitabine: a phase I study. Invest New Drugs. 1999; 17: 5762.
  • 21
    Hidalgo M, Castellano D, Paz-Ares L, et al. Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer. J Clin Oncol. 1999; 17: 585592.
  • 22
    Berlin JD, Alberti DB, Arzoomanian RZ, et al. A phase I study of gemcitabine, 5-fluorouracil and leucovorin in patients with advanced, recurrent, and/or metastatic solid tumors. Invest New Drugs. 1998; 16: 325330.
  • 23
    Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205216.
  • 24
    Duffy D, Santner T. Confidence intervals for a binomial parameter based on multistage tests. Biometrics. 1987; 43: 8193.
  • 25
    Kaplan E, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc. 1958; 53: 457481.
  • 26
    Kubicka S, Rudolph KL, Tietze MK, et al. Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas. Hepatogastroenterology. 2001; 48: 783789.
  • 27
    Valencak J, Kornek GV, Raderer M, et al. Gemcitabine for the treatment of advanced biliary tract carcinomas: evaluation of two different dose regimens. Onkologie. 1999; 22: 498501.
  • 28
    Murad AM, Guimaraes RC, Aragao BC, et al. Phase II trial of the use of gemcitabine and 5-fluorouracil in the treatment of advanced pancreatic and biliary tract cancer. Am J Clin Oncol. 2003; 26: 151154.
  • 29
    Knox JJ, Hedley D, Oza A, et al. Phase II trial of gemcitabine plus capecitabine (GemCap) in patients with advanced or metastatic adenocarcinoma of the biliary tract [abstract]. Proc Am Assoc Cancer Res. 2003; 22: 317a.
  • 30
    Malik IA, Aziz Z, Zaidi SH, et al. Gemcitabine and cisplatin is a highly effective combination chemotherapy in patients with advanced cancer of the gallbladder. Am J Clin Oncol. 2003; 26: 174177.
  • 31
    Baluch S, Lau J, Dhillon T, et al. A well tolerated and highly effective regimen for locally advanced and metastatic biliary tract cancers with gemcitabine and cisplatin [abstract]. Proc Am Assoc Cancer Res. 2003; 22: 367.
  • 32
    Thongprasert S, Napapan S, Charoentum C, et al. Phase II study of gemcitabine plus cisplatin in biliary tract cancer [abstract]. Proc Am Assoc Cancer Res. 2003; 22: 304.